MX2024000908A - Metodo para producir derivado de arilamida. - Google Patents

Metodo para producir derivado de arilamida.

Info

Publication number
MX2024000908A
MX2024000908A MX2024000908A MX2024000908A MX2024000908A MX 2024000908 A MX2024000908 A MX 2024000908A MX 2024000908 A MX2024000908 A MX 2024000908A MX 2024000908 A MX2024000908 A MX 2024000908A MX 2024000908 A MX2024000908 A MX 2024000908A
Authority
MX
Mexico
Prior art keywords
arylamide derivative
fluoropyridin
amino
pharmaceutically acceptable
making
Prior art date
Application number
MX2024000908A
Other languages
English (en)
Spanish (es)
Inventor
Kazuaki KUWATA
Hidehisa SOMEYA
Original Assignee
Chugai Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Chugai Pharmaceutical Co Ltd filed Critical Chugai Pharmaceutical Co Ltd
Publication of MX2024000908A publication Critical patent/MX2024000908A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/72—Nitrogen atoms
    • C07D213/76—Nitrogen atoms to which a second hetero atom is attached
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4436—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a heterocyclic ring having sulfur as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
    • B01J31/00—Catalysts comprising hydrides, coordination complexes or organic compounds
    • B01J31/16—Catalysts comprising hydrides, coordination complexes or organic compounds containing coordination complexes
    • B01J31/22—Organic complexes
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
    • B01J31/00—Catalysts comprising hydrides, coordination complexes or organic compounds
    • B01J31/16—Catalysts comprising hydrides, coordination complexes or organic compounds containing coordination complexes
    • B01J31/24—Phosphines, i.e. phosphorus bonded to only carbon atoms, or to both carbon and hydrogen atoms, including e.g. sp2-hybridised phosphorus compounds such as phosphabenzene, phosphole or anionic phospholide ligands
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B61/00—Other general methods
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/72—Nitrogen atoms
    • C07D213/73—Unsubstituted amino or imino radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/50—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom condensed with carbocyclic rings or ring systems
    • C07D333/52—Benzo[b]thiophenes; Hydrogenated benzo[b]thiophenes
    • C07D333/62—Benzo[b]thiophenes; Hydrogenated benzo[b]thiophenes with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the hetero ring
    • C07D333/66—Nitrogen atoms not forming part of a nitro radical
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F5/00—Compounds containing elements of Groups 3 or 13 of the Periodic Table
    • C07F5/02—Boron compounds

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Inorganic Chemistry (AREA)
  • Materials Engineering (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
  • Pyridine Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
MX2024000908A 2021-07-21 2022-07-20 Metodo para producir derivado de arilamida. MX2024000908A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2021120977 2021-07-21
PCT/JP2022/028187 WO2023003014A1 (ja) 2021-07-21 2022-07-20 アリールアミド誘導体の製造方法

Publications (1)

Publication Number Publication Date
MX2024000908A true MX2024000908A (es) 2024-02-07

Family

ID=84980009

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2024000908A MX2024000908A (es) 2021-07-21 2022-07-20 Metodo para producir derivado de arilamida.

Country Status (12)

Country Link
US (1) US20240327355A1 (enExample)
EP (1) EP4375273A4 (enExample)
JP (2) JP7268255B1 (enExample)
KR (1) KR102671612B1 (enExample)
CN (1) CN117677607A (enExample)
AR (1) AR126517A1 (enExample)
AU (1) AU2022312992A1 (enExample)
CA (1) CA3226827A1 (enExample)
IL (1) IL310123A (enExample)
MX (1) MX2024000908A (enExample)
TW (1) TW202321198A (enExample)
WO (1) WO2023003014A1 (enExample)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2026522033A (ja) * 2023-07-06 2026-07-03 華健未来(成都)科技股▲フン▼有限公司 芳香族アミド誘導体およびその使用
WO2025063275A1 (ja) 2023-09-21 2025-03-27 中外製薬株式会社 アリールアミド誘導体の製造方法
AU2024417154A1 (en) * 2024-01-01 2026-08-13 Huajian Future (Chengdu) Technology Co., Ltd. Aromatic hydrazide derivative and medical use thereof
CN118604164B (zh) * 2024-05-15 2025-06-06 石家庄四药有限公司 一种非奈利酮中间体中杂质的检测方法
WO2026098657A1 (zh) * 2024-11-08 2026-05-15 先声再明医药股份有限公司 作为mek抑制剂的杂环化合物

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4931419B2 (ja) * 2003-09-19 2012-05-16 中外製薬株式会社 新規4−フェニルアミノ−ベンズアルドオキシム誘導体並びにそのmek阻害剤としての使用
MY144232A (en) * 2004-07-26 2011-08-15 Chugai Pharmaceutical Co Ltd 5-substituted-2-phenylamino benzamides as mek inhibitors
AR059339A1 (es) 2006-02-09 2008-03-26 Chugai Pharmaceutical Co Ltd Derivados de la cumarina para trastornos proliferativos de celulas, composicion farmaceutica y agente terapeutico que los contiene
PT2344474E (pt) * 2008-09-02 2015-12-28 Novartis Ag Derivados de picolinamida como inibidores de cinase
BR112012010519A2 (pt) * 2009-11-04 2017-12-05 Novartis Ag derivados de sulfonamida heterocíclicos
JP2016034900A (ja) * 2012-11-26 2016-03-17 中外製薬株式会社 5−置換−2−フェニルアミノ−ベンズアミド類の製造方法
AR121078A1 (es) * 2020-01-22 2022-04-13 Chugai Pharmaceutical Co Ltd Derivados de arilamida con actividad antitumoral
KR20230122174A (ko) * 2020-07-22 2023-08-22 추가이 세이야쿠 가부시키가이샤 아릴 아마이드 유도체를 포함하는 조성물
WO2022018875A1 (ja) * 2020-07-22 2022-01-27 中外製薬株式会社 アリールアミド誘導体を含む細胞増殖性疾患の治療又は予防用医薬組成物

Also Published As

Publication number Publication date
KR20230152797A (ko) 2023-11-03
CN117677607A (zh) 2024-03-08
JP2023084138A (ja) 2023-06-16
KR102671612B1 (ko) 2024-05-31
AU2022312992A1 (en) 2024-02-29
EP4375273A1 (en) 2024-05-29
JPWO2023003014A1 (enExample) 2023-01-26
EP4375273A4 (en) 2025-05-21
US20240327355A1 (en) 2024-10-03
JP7268255B1 (ja) 2023-05-02
TW202321198A (zh) 2023-06-01
CA3226827A1 (en) 2023-01-26
IL310123A (en) 2024-03-01
WO2023003014A1 (ja) 2023-01-26
AR126517A1 (es) 2023-10-18

Similar Documents

Publication Publication Date Title
AR126517A1 (es) Método para producir un derivado de aril amida
CL2023000199A1 (es) Composición que contiene un derivado de arilamida
AR117101A1 (es) Síntesis mejorada del intermedio clave del compuesto inhibidor de g12c de kras
AR114631A1 (es) Métodos e intermedios para preparar compuestos de piridina
MX2021006908A (es) Compuesto agonista del receptor thrb y metodo de preparacion y uso del mismo.
CU24735B1 (es) Compuestos heterocíclicos como agonistas del receptor de activación expresado en las células mieloides 2
CO2018009124A2 (es) Análogos de cannabidiol biológicamente activos
CL2021002234A1 (es) Inhibidor de la interacción proteína-proteína wdr5 basado en anilina, método para preparar el mismo y uso del mismo
CY1112237T1 (el) Παραγωγα 5-υδροξυ-βενζοθειαζολης που εχουν ενεργοτητα αγωνιστη βητα-2-αδρενοϋποδοχεα
AR069165A1 (es) Derivados de 4-bencilamino-1-carboxacilpiperidina como inhibidores de cetp utiles para el tratamiento de hiperlipidemia
JP2011506402A5 (enExample)
JOP20210039B1 (ar) مركبات بيريدين 6،2 - ديامينو
MX2019010324A (es) Método para preparar poli(carbonatos de éter).
NZ602710A (en) Use of novel pan-cdk inhibitors for treating tumors
MX2022006910A (es) Tratamiento para la leucemia mieloide aguda o para el síndrome mielodisplásico.
MX2023011176A (es) Tratamiento de hidradenitis supurativa con orismilast.
PE20200727A1 (es) Compuestos heteroaromaticos sustituidos con cicloolefinas y su uso
RU2019127038A (ru) N1-(4-(5-(циклопропилметил)-1-метил-1h-пиразол-4-ил)пиридин-2-ил)циклогексан-1,4-диаминовые производные и родственные соединения в качестве ингибиторов сk1 и/или irak1 для лечения рака
RU2004136989A (ru) Цианогуанидиновые пролекарства
ES2421605T3 (es) Inhibidores de trastorno isquémico o enfermedades
CL2022003054A1 (es) Síntesis de intermedios de vinil ciclobutilo
BR112023018246A2 (pt) Formas de sal e sólidas de um inibidor de cinase
BR112020020549A8 (pt) Novo processo para síntese de um composto fenoxi diaminopirimidina
AR067534A1 (es) Proceso para la preparacion de trifluoroalquil - fenil sulfonamidas y de sulfonamidas heterociclicas
UY39026A (es) Proceso químico para la síntesis de compuestos de piridazina sustituida